Amgen Inc. (NASDAQ:AMGN) Q3 2023 Earnings Conference Call October 31, 2023 8:00 AM ET
Company Participants
Justin Claeys - VP, IR
Robert Bradway - Chairman & CEO
Murdo Gordon - EVP, Global Commercial Operations
Vikram Karnani - Executive, Rare Disease Business
David Reese - EVP, Research & Development
Peter Griffith - CFO
Conference Call Participants
Michael Yee - Jefferies
Yaron Werber - TD Cowen
Terence Flynn - Morgan Stanley
Salveen Richter - Goldman Sachs
Jay Olson - Oppenheimer
Umer Raffat - Evercore ISI
Robyn Karnauskas - Truist Securities
David Risinger - Leerink Partners
Chris Raymond - Piper Sandler
Mohit Bansal - Wells Fargo
Gregory Renza - RBC Capital Markets
Geoff Meacham - Bank of America
Chris Schott - JPMorgan
Evan Seigerman - BMO
Tim Anderson - Wolfe Research
Colin Bristow - UBS
Operator
My name is Julianne, and I'll be your conference facilitator today for Amgen's Third Quarter 2023 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the conclusion of the last speaker's prepared remarks. [Operator Instructions]
I would now like to introduce Justin Claeys, Vice President of Investor Relations. Mr. Claeys, you may now begin.
Justin Claeys
Thank you, Julianne. Good morning, and welcome to our third quarter 2023 earnings call. Bob Bradway will lead the call and be followed by a broader review of our performance by Murdo Gordon, Vikram Karnani, who joined Amgen from Horizon Therapeutics following the October 6, 2023 acquisition close, Dave Reese and Peter Griffith.
Given the timing of these Horizon Therapeutics acquisition close, our third quarter results do not include any contribution from Horizon. Vikram will provide select information from Horizon's third quarter product sales for future context. You should have received a link to our slides that we have posted.
Through the course of our discussion today, we will make some forward-looking statements and use non-GAAP financial measures to describe our performance. And just a reminder that actual results can vary materially.
I would now like to turn the call over to Bob.
Robert Bradway
Okay. Thank you, Justin and thank all of you for joining our call. It's an exciting time here at Amgen. And we're continuing to execute well this year, serving many more patients around the world with medicines such as Repatha, EVENITY and Tezspire, advancing a number of promising first-in-class medicines rapidly through our pipeline and preparing for our next wave of biosimilar launches.